60 x 300mg vegcaps. **PLEASE be aware and a careful shopper,
this product is a full 300 mg active R-lipoic acid, not 210mg
active RLA as some competitor products.** When comparing
"apples to apples" cost per active mg per capsule, our 300mg is
very cost competitive.
This material is the stable salt form (Na-RALA) of R-Lipoic
Acid. Researchers believe that R-lipoic acid may be up to 8 times
more active than Alpha-Lipoic Acid.
Unstabilized RLA can contain harmful heavy metals and residual
solvents that are very difficult to remove. Geronova's processing
removes all traces of residual solvents from the raw material.
Na-RALA is much more stable than RLA even at elevated
temperatures. Heated to over 150° C for 6 hours there is no loss of
activity, and polymer formation was undetectable. Pure RLA would
instantaneously polymerize under these conditions.
This R-Lipoic Acid requires no refrigeration and does not
polymerize, whereas unstabilized RLA polymerizes at temperatures
slightly above ambient. The polymerization of RLA is accelerated by
light, heat and moisture.
This form of r-lipoic acid (Na-RALA) does NOT offer the natural
sustained release action of the MCT transported, liquicap, GeroNova
products (R-PLUS, R-Plus CoQ10, Mito-GOLD).
Serving Size: 1 Capsule.
Servings per container: 60
R-Lipoic Acid 300mg *
[derived from 435 mg Sodium-R-Lipoic Acid]
*Daily value not established
Sodium bicarbonate (12%), magnesium stearate, vegetarian
Directions: Take 1 capsule daily, or as recommended by your
health care provider, with or without meals.
K-RALA® requires no refrigeration and does not polymerize,
whereas RLA polymerizes at temperatures slightly above ambient. The
polymerization of RLA is accelerated by light, heat and
BIOAVAILABILITY refers to the amount (or percent of dose) of RLA
that reaches the systemic blood circulation and is therefore
available for use by the cells. Bioavailability is dependent upon
absorption. In pharmacology, the absolute bioavailability of RLA
measures the availability of RLA in the systemic circulation. This
is determined by obtaining a blood plasma concentration over time,
referred to as the AUC (area under the curve). Relative
bioavailability compares the bioavailability of one product to
another. In a preliminary human clinical trial, the AUC for
GeroNova's Bio-Enhanced lipoic acid was 50 times higher than that
of unstabilized RLA.
From TERESA FRIEDMAN of HOUSTON, Texas on 5/4/2013.
is currently empty